FDA Approves Osimertinib + Chemotherapy for EGFR-mutated Non-small Cell Lung Cancer
FDA Grants Accelerated Approval to Lifileucel for Unresectable or Metastatic Melanoma
FDA Approves Tepotinib for Metastatic non-small Cell Lung Cancer
FDA Approves Irinotecan Liposome for First-line Treatment of Metastatic Pancreatic Adenocarcinoma
FDA Approves Erdafitinib for Locally Advanced or Metastatic Urothelial Carcinoma
FDA Approves Pembrolizumab + CRT for FIGO 2014 Stage III-IVA Cervical Cancer
FDA Approves Iptacopan for Patients with Paroxysmal Nocturnal Hemoglobinuria
FDA Approves Enfortumab vedotin-ejfv + Pembrolizumab for Locally Advanced or Metastatic Urothelial Cancer
FDA Approves Belzutifan for Advanced Renal Cell Carcinoma
FDA Approves Eflornithine for Adult and Pediatric Patients with HRNB
FDA Approves pirtobrutinib for Chronic Lymphocytic Leukemia + Small Lymphocytic Lymphoma
FDA Approves Nirogacestat for Desmoid Tumors
FDA Approves Capivasertib + Fulvestrant for Breast Cancer
FDA Approves Pembrolizumab + Chemotherapy for HER2-negative GEJ Junction Adenocarcinoma
FDA Approves Repotrectinib for ROS1-positive NSCLC
FDA Approves Fruquintinib in Refractory Metastatic Colorectal Cancer
CMS Releases PFS For 2024
FDA Approves Toripalimab-tpzi for Nasopharyngeal Carcinoma
FDA Approves Ivosidenib for Myelodysplastic Syndromes
FDA Expands Pediatric Indication for Entrectinib and Approves New Pellet Formulation
FDA Approves Nivolumab for Adjuvant Treatment of Stage IIB/C Melanoma
FDA Approves Encorafenib + Binimetinib for NSCLC with a BRAF V600E Mutation
FDA Approves Momelotinib For Myelofibrosis Patients with Anemia
FDA Approves New and Updated Indications for Temozolomide Under Project Renewal
FDA Approves Luspatercept-aamt for Adults with Lower-Risk MDS
New ASHP Survey: Critical Shortages of Cancer Drugs Pose Dangers to Patient Care
FDA Approves Melphalan as a Liver-directed Treatment for Uveal Melanoma
FDA Approves FoundationOne®CDx as a Companion Diagnostic for Niraparib and Abiraterone acetate
FDA Grants Accelerated Approval to Elranatamab-bcmm for Multiple Myeloma
FDA Approves Niraparib and Abiraterone acetate + Prednisone for BRCA-mutated mCRPC
